# An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

> **NCT05522387** · PHASE2 · TERMINATED · sponsor: **Inmune Bio, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders

## Interventions

- **DRUG:** XPro1595

## Key facts

- **NCT ID:** NCT05522387
- **Lead sponsor:** Inmune Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-21
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-07-05
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Sponsor resource allocation
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522387, "An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05522387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*